Bio-Rad Laboratories(NYSE:BIO) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $516.78M. Analysts estimated a revenue of $498.35M. Earnings per share were $1.02. Analysts had estimated an EPS of $0.92.
Bio-Rad Laboratories (BIO) shares turned negative on Fridays trading session with the shares closing down -0.46 points or -0.30% at a volume of 1,01,116. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $154.91. The peak price level was also seen at $154.91 while the days lowest was $153.27. Finally the shares closed at $153.98. The 52-week high of the shares is $158.5 while the 52-week low is $122.03. According to the latest information available, the market cap of the company is $4,531 M.
Several Insider Transactions has been reported to the SEC. On Jun 14, 2016, Shannon Hall (Executive Vice President) sold 1,572 shares at $145.30 per share price.Also, On Jun 13, 2016, Alice N Schwartz (director 10% owner) sold 7,000 shares at $147.02 per share price.On Mar 14, 2016, Christine A Tsingos (EVP and CFO) sold 6,630 shares at $137.81 per share price, according to the Form-4 filing with the securities and exchange commission.
Bio-Rad Laboratories Inc. (Bio-Rad) manufactures and supplies products and systems used for the life science research healthcare analytical chemistry and other markets. The Company offers products to separate complex chemical and biological materials and to identify analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. The Companys Life Science segment develops manufactures and markets a range of over 5000 reagents apparatus and laboratory instruments. The Companys Clinical Diagnostics segment designs manufactures sells and supports test systems informatics systems test kits and quality controls that serve clinical laboratories in the global diagnostics market. Bio-Rads product brands include Droplet Digital and BioPlex. As of December 31 2014 the Company had direct distribution channels in over 35 countries outside the United States through subsidiaries.